Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | KAT7 | O95251 | 1/20 | 0.40 |
| ▸ | KAT6B | Q8WYB5 | 1/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.40 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | AGXT | P21549 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14822759 | 0.87 | RIPK1 (0.44) | CYP3A4BRD4HDAC1KAT7KAT6B | |
| SCHEMBL1953678 | 0.84 | BRD4 (0.43) | CYP3A4BRD4KLKB1HDAC1HTT | |
| SCHEMBL3809851 | 0.84 | TP53 (0.45) | CYP3A4BRD4KLKB1HDAC1HTT | |
| SCHEMBL3806937 | 0.84 | SMN1; SMN2 (0.48) | KDM4ESMN1; SMN2BRD4HTTGAA | |
| SCHEMBL5299707 | 0.84 | BRD4 (0.43) | CYP3A4KDM4ESMN1; SMN2BRD4KLKB1 | |
| SCHEMBL17221362 | 0.81 | KLKB1 (0.47) | CYP3A4BRD4KLKB1HDAC1KAT7 | |
| SCHEMBL7465706 | 0.81 | ALDH1A1 (0.56) | CYP3A4KDM4ESMN1; SMN2BRD4HDAC1 | |
| SCHEMBL30047375 | 0.81 | ALDH1A1 (0.56) | CYP3A4KDM4ESMN1; SMN2BRD4HDAC1 | |
| SCHEMBL27760047 | 0.80 | KDM4E (0.49) | KDM4ESMN1; SMN2BRD4KLKB1KAT7 | |
| SCHEMBL31691366 | 0.79 | HTT (0.60) | BRD4KLKB1HDAC1HDAC7HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103097387-B | Ring-fused pyrimidines and triazines and use thereof for treating and/or preventing cardiovascular diseases | 拜耳知识产权有限责任公司 | 2016-11-02 | — | — | CN | disclosed |
| EP-3048155-A1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC COMPONENTS | cynora GmbH (DE) | 2016-07-27 | — | — | EP | disclosed |
| EP-3048156-A1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC COMPONENTS | cynora GmbH (DE) | 2016-07-27 | — | — | EP | disclosed |
| CN-104011027-A | Use of lonidamine analogs for fertility regulation | UNIV KANSAS | 2014-08-27 | — | — | CN | disclosed |
| CN-103097387-A | Ring-fused pyrimidines and triazines and use thereof for treating and/or preventing cardiovascular diseases | BAYER IP GMBH | 2013-05-08 | — | — | CN | disclosed |
| US-8410269-B2 | Phosphorescent iridium complex with non-conjugated cyclometalated ligands, synthetic method of preparing the same and phosphorescent organic light emitting diode thereof | NATIONAL TSING HUA UNIVERSITY (TW) | 2013-04-02 | — | — | US | disclosed |
| US-20110313162-A1 | PHOSPHORESCENT IRIDIUM COMPLEX WITH NON-CONJUGATED CYCLOMETALATED LIGANDS, SYNTHETIC METHOD OF PREPARING THE SAME AND PHOSPHORESCENT ORGANIC LIGHT EMITTING DIODE THEREOF | NATIONAL TSING HUA UNIVERSITY (TW) | 2011-12-22 | — | — | US | disclosed |
| US-20110313161-A1 | PHOSPHORESCENT IRIDIUM COMPLEX WITH NON-CONJUGATED CYCLOMETALATED LIGANDS, SYNTHETIC METHOD OF PREPARING THE SAME AND PHOSPHORESCENT ORGANIC LIGHT EMITTING DIODE THEREOF | NATIONAL TSING HUA UNIVERSITY (TW) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313161-A1 | PHOSPHORESCENT IRIDIUM COMPLEX WITH NON-CONJUGATED CYCLOMETALATED LIGANDS, SYNTHETIC METHOD OF PREPARING THE SAME AND PHOSPHORESCENT ORGANIC LIGHT EMITTING DIODE THEREOF | LIG3, LIG4, LIG1 | CYP3A4 4333/4885KDM4E 3694/4885SMN1; SMN2 4318/4885 |
| US-20110313162-A1 | PHOSPHORESCENT IRIDIUM COMPLEX WITH NON-CONJUGATED CYCLOMETALATED LIGANDS, SYNTHETIC METHOD OF PREPARING THE SAME AND PHOSPHORESCENT ORGANIC LIGHT EMITTING DIODE THEREOF | LIG3, LIG4, LIG1 | CYP3A4 4333/4885KDM4E 3694/4885SMN1; SMN2 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.